Checkpoint Therapeutics Inc. (CKPT) has secured FDA approval for its lead asset Cosibelimab for the treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation.
Cutaneous squamous cell carcinoma, the second most common type of skin cancer in the United States, is estimated to affect around 1.8 million individuals each year, according to the Skin Cancer Foundation. The U.S. cSCC market opportunity is valued at over $1 billion.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.